GIST under imatinib therapy

Seminars in Diagnostic Pathology

Volumn 23, Issue 2, 2006, Pages 84-90

  Sciot, Raf ^a   Debiec Rychter, Maria ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Genotype; GIST; Imatinib; Phenotype; Treatment effect

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SUNITINIB;

ARTICLE; CANCER CONTROL; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE RESISTANCE; DRUG EFFECT; GASTROINTESTINAL STROMAL TUMOR; GENOTYPE; HUMAN; IMMUNOPHENOTYPING; INDUCED MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RESPONSE TIME; STATISTICAL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR RESISTANCE;

AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENOTYPE; HUMANS; LEIOMYOSARCOMA; MALE; MIDDLE AGED; PHENOTYPE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 33750624138     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2006.08.005     Document Type: Article

References (36)

1. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 1052 (2001) 1052-1056
2. Van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours. A phase I study. Lancet 358 (2001) 1421-1423
3. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
4. Benjamin R.S., Rankin C., Fletcher C., et al. Phase III dose-randomized study of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 22 (2003) 814
5. Debiec-Rychter M., Dumez H., Judson J., et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumors entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40 (2004) 689-695
6. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
7. Debiec-Rychter M., Sciot R., Le Cesne A., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42 (2006) 1093-1103
8. Blay J.Y., Bonvalot S., Casali P., et al. Consensus meeting for the managament of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 16 (2005) 566-578
9. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 (2003) 4342-4349
10. Tornillo L., and Terracciano L.M. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 59 (2006) 557-563
11. Blanke C.D., Demitri G.D., Von Mehren M.C., et al. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. J Clin Oncol 24 (2006) 9528
12. Bauer S., Hartmann J.T., de Wit M., et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117 (2005) 316-325
13. Antonescu C.R., Besmer P., Guo T., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11 (2005) 4182-4190
14. Scaife C.L., Hunt K.K., Patel S.R., et al. Is there a role for surgery in patients with "unresectable" cKit+ gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg 186 (2003) 665-669
15. Chacon M., Roca E., Huertas E., et al. CASE 3. Pathologic complete remission of metastatic gastrointestinal stromal tumor after imatinib mesylate. J Clin Oncol 23 (2005) 1580-1582
16. Melichar B., Voboril Z., Nozicka J., et al. Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy. Intern Med 44 (2005) 1163-1168
17. Hogenauer C., Langner C., Lipp R.W., et al. Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI571): effect of low dosage in an advanced tumour with exon 11 mutation. Eur J Gastroenterol Hepatol 15 (2003) 323-327
18. Bauer S., Lang H., Schutte J., et al. Complete remission with imatinib in metastatic gastrointestinal stromal tumors. J Clin Oncol 23 (2005) 6800-6801
19. Corless C.L., Schroeder A., Griffith D., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23 (2005) 1-8
20. Duensing A., Medeiros F., McConarty B., et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23 (2004) 3999-4006
21. Trent J.C., Choi K., Hunt H., et al. Apoptotic and anti-vascular activity of imatinib in GIST patients. J Clin Oncol 23 (2005) 9001
22. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15 (2004) 275-286
23. Bagley R.G., Weber W., Rouleau C., et al. Pericytes and endothelial precursor cells: cellular interactions and contributions to malignanacy. Cancer Res 65 (2005) 9741-9750
24. + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7 (2005) 870-879
25. Seandal M., Shia J., Linkov I., et al. The activity of sunitinib (SU11248) against gastrointestinal stromal tumor (GIST) appears to be distinct from its anti-angiogenic effects. Clin Cancer Res (2006) in press
26. Debiec-Rychter M., Cools J., Dumez H., et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128 (2005) 270-279
27. Wardelmann E., Thomas N., Merkelbach-Bruse S., et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 6 (2005) 249-251
28. Fletcher J.A., Corless C.L., Dimitrijevic S., et al. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol 22 (2003) 815
29. Wardelmann E., Merkelbach-Bruse S., Pauls K., et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12 (2006) 1743-1749
30. Chen L.L., Trent J.C., Wu E.F., et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64 (2004) 5913-5919
31. Grimpen F., Yip D., McArthur G., et al. Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour. Lancet Oncol 6 (2005) 724-727
32. Tamborini E., Bonadiman L., Greco A., et al. A new mutation in the KIT ATP pocket causes acquiered resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127 (2004) 294-299
33. Tamborini E, Pricl S, Negri T, et al: Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene (online June 2006)
34. Wakai T., Kanada T., Hirota S., et al. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 90 (2004) 2059-2061
35. Heinrich M.C., Mali R.G., Corless C.L., et al. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol 24 (2006) 9502
36. Pauwels P., Debiec-Rychter M., Stul M., et al. Changing phenotype of gastrointestinal stromal tumors under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 47 (2005) 41-47